<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01767324</url>
  </required_header>
  <id_info>
    <org_study_id>FGN-NSR-2012-001</org_study_id>
    <nct_id>NCT01767324</nct_id>
  </id_info>
  <brief_title>Site Selection for Intracutaneous Saline Delivery</brief_title>
  <official_title>Exploratory Evaluation of Injection Sites in Healthy Subjects Receiving Saline Delivered by a Non-Significant Risk Investigational Device Utilizing a Micro-Needle Array</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FluGen Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Accelovance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>FluGen Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this exploratory study is to select the optimal body site for intracutaneous
      delivery of 0.5 milliliters of saline from the FLUGEN 101.2 microneedle-based device.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Test ability to inject saline into various sites on body.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective is to evaluate the safety and tolerability/reactogenicity of saline delivery from the FLUGEN 101.2 microneedle-based device as evidenced by change of dose site appearance over time.</measure>
    <time_frame>30 minutes, 24 hours, 1 week</time_frame>
    <description>Observe injection sites for change of appearance post-dose including wheal formation or resolution.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>A secondary objective of this study is to evaluate the mechanical elimination of fluid from the device.</measure>
    <time_frame>3 minutes</time_frame>
    <description>Evaluate ability of device to dispense targeted dose volume.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Intracutaneous Drug Delivery</condition>
  <arm_group>
    <arm_group_label>Injection to deltoid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Deliver saline from FLUGEN 101.2 microneedle-based delivery device.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Injection to forearm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Deliver saline from FLUGEN 101.2 microneedle-based delivery device.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Injection to thigh</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Deliver saline from FLUGEN 101.2 microneedle-based delivery device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Injection to deltoid</intervention_name>
    <description>Deliver 0.5 milliliters of saline intradermally</description>
    <arm_group_label>Injection to deltoid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Injection to forearm</intervention_name>
    <description>Deliver 0.5 milliliters of saline intradermally</description>
    <arm_group_label>Injection to forearm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Injection to thigh</intervention_name>
    <description>Deliver 0.5 milliliters of saline intradermally</description>
    <arm_group_label>Injection to thigh</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to read and/or understand and sign the Informed Consent Form

        Exclusion Criteria:

          -  Medical history of acute or chronic skin disease

          -  Active skin allergy or acute skin infection, tattoo(s), scars, sunburn or skin
             abnormalities at any prospective injection site

          -  Hirsute at any prospective injection site

          -  Diabetes

          -  High levels of anxiety or depression or history of psychosis

          -  Abuse of alcohol or use of other drugs of abuse including tobacco

          -  Pregnant or breastfeeding women

          -  Any medical condition that may interfere with study protocol adherence including
             completion of study activities

          -  Foreseeable inability to complete the study as scheduled.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renee Herber</last_name>
    <role>Study Director</role>
    <affiliation>FluGen Inc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Murray A Kimmel, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Accelovance</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Accelovance Inc</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2013</study_first_submitted>
  <study_first_submitted_qc>January 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2013</study_first_posted>
  <last_update_submitted>July 31, 2017</last_update_submitted>
  <last_update_submitted_qc>July 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>microneedle-based array</keyword>
  <keyword>hollow microneedle</keyword>
  <keyword>intracutaneous</keyword>
  <keyword>drug delivery</keyword>
  <keyword>vaccine delivery</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

